These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 16079613)

  • 21. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
    Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
    Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature.
    Petit-Jean E; Buclin T; Guidi M; Quoix E; Gourieux B; Decosterd LA; Gairard-Dory AC; Ubeaud-Séquier G; Widmer N
    Ther Drug Monit; 2015 Feb; 37(1):2-21. PubMed ID: 24831652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Target concentration intervention in oncology: where are we at?
    Saleem M; Dimeski G; Kirkpatrick CM; Taylor PJ; Martin JH
    Ther Drug Monit; 2012 Jun; 34(3):257-65. PubMed ID: 22585183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose calculation of anticancer drugs.
    Gao B; Klumpen HJ; Gurney H
    Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1307-19. PubMed ID: 18798700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The (ir)relevance of plasma protein binding of anticancer drugs.
    Sparreboom A; Nooter K; Loos WJ; Verweij J
    Neth J Med; 2001 Oct; 59(4):196-207. PubMed ID: 11578795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An overview of therapeutic anticancer drug monitoring based on surface enhanced (resonance) Raman spectroscopy (SE(R)RS).
    Li C; Ye Z; Xu Y; Bell SEJ
    Analyst; 2020 Sep; 145(19):6211-6221. PubMed ID: 32794527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis.
    Kastrissios H; Ratain MJ
    Cancer Invest; 2001; 19(1):57-64. PubMed ID: 11291557
    [No Abstract]   [Full Text] [Related]  

  • 28. Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research.
    Reilly JJ; Workman P
    Cancer Chemother Pharmacol; 1994; 34(1):3-13. PubMed ID: 8174199
    [No Abstract]   [Full Text] [Related]  

  • 29. [Development of an individualized therapy for establishing the optimal dosage by the pharmacokinetics profiles of anticancer agents].
    Hamada A
    Yakugaku Zasshi; 2005 Aug; 125(8):631-7. PubMed ID: 16079613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Practical treatment guide for dose individualisation in cancer chemotherapy.
    Canal P; Chatelut E; Guichard S
    Drugs; 1998 Dec; 56(6):1019-38. PubMed ID: 9878990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amrubicin for non-small-cell lung cancer and small-cell lung cancer.
    Kurata T; Okamoto I; Tamura K; Fukuoka M
    Invest New Drugs; 2007 Oct; 25(5):499-504. PubMed ID: 17628745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic drug monitoring in cancer chemotherapy.
    Bach DM; Straseski JA; Clarke W
    Bioanalysis; 2010 May; 2(5):863-79. PubMed ID: 21083218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic drug monitoring in cancer management.
    Galpin AJ; Evans WE
    Clin Chem; 1993 Nov; 39(11 Pt 2):2419-30. PubMed ID: 8222253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
    Paci A; Veal G; Bardin C; Levêque D; Widmer N; Beijnen J; Astier A; Chatelut E
    Eur J Cancer; 2014 Aug; 50(12):2010-9. PubMed ID: 24889915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 2.